RT Journal Article
SR Electronic
T1 Treatment with human umbilical cord-derived mesenchymal stem cells for COVID-19 patients with lung damage: a randomised, double-blind, placebo-controlled phase 2 trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.15.20213553
DO 10.1101/2020.10.15.20213553
A1 Shi, Lei
A1 Huang, Hai
A1 Lu, Xuechun
A1 Yan, Xiaoyan
A1 Jiang, Xiaojing
A1 Xu, Ruonan
A1 Wang, Siyu
A1 Zhang, Chao
A1 Yuan, Xin
A1 Xu, Zhe
A1 Huang, Lei
A1 Fu, Jun-Liang
A1 Li, Yuanyuan
A1 Zhang, Yu
A1 Yao, Weiqi
A1 Liu, Tianyi
A1 Song, Jinwen
A1 Sun, Liangliang
A1 Yang, Fan
A1 Zhang, Xin
A1 Zhang, Bo
A1 Shi, Ming
A1 Meng, Fanping
A1 Song, Yanning
A1 Yu, Yongpei
A1 Wen, Jiqiu
A1 Li, Qi
A1 Mao, Qing
A1 Maeurer, Markus
A1 Zumla, Alimuddin
A1 Yao, Chen
A1 Xie, Wei-Fen
A1 Wang, Fu-Sheng
YR 2020
UL http://medrxiv.org/content/early/2020/10/21/2020.10.15.20213553.abstract
AB BACKGROUND Treatment of severe Corona Virus Disease 2019 (COVID-19) is challenging. We performed a phase 2 trial to assess the efficacy and safety of human umbilical cord-mesenchymal stem cells (UC-MSCs) to treat severe COVID-19 patients with lung damage, based on our phase 1 data.METHODS In this randomized, double-blind, and placebo-controlled trial, we recruited 101 severe COVID-19 patients with lung damage. They were randomly assigned to receive either UC-MSCs (4 × 107 cells per infusion) or placebo on day 0, 3, and 6. The primary endpoint was an altered proportion of whole lung lesion volumes from baseline to day 28. Other imaging outcomes, 6-minute walk test, maximum vital capacity, diffusing capacity, and adverse events were recorded and analysed.RESULTS 100 COVID-19 patients were finally recruited to receive either UC-MSCs (n = 65) or placebo (n = 35). UC-MSCs administration exerted numerical improvement in whole lung lesion volume from baseline to day 28 compared with the placebo (the median difference was -13.31%, 95%CI -29.14%, 2.13%, P=0.080). UC-MSCs significantly reduced the proportions of solid component lesion volume compared with the placebo (median difference: -15.45%; 95% CI -30.82%, -0.39%; P=0.043). The 6-minute walk test showed an increased distance in patients treated with UC-MSCs (difference: 27.00 m; 95% CI 0.00, 57.00; P=0.057). The incidence of adverse events was similar in the two groups.CONCLUSIONS UC-MSCs treatment is a safe and potentially effective therapeutic approach for COVID-19 patients with lung damage. (Funded by The National Key R&D Program of China and others. ClinicalTrials.gov number, NCT04288102.)Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04288102Funding StatementThis trial was supported by The National Key R&D Program of China (2020YFC0841900, 2020YFC0844000, 2020YFC08860900); The Innovation Groups of the National Natural Science Foundation of China (81721002); The National Science and Technology Major Project (2017YFA0105703). The funder of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of this report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Clinical Trial Ethics Committee of Fifth Medical Cente, Chinese PLA General Hospital (2020-013-D), the Medical Ethics Committee of Wuhan Huoshenshan Hospital(HSSLL004), the Medical Ethics Committee of Maternal and Child Hospital of Hubei Province(2020IEC001).Written informed consent was obtained from all the enrolled patients or their legal representatives if they were unable to provide consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred in the manuscript are available on resonable request to Fu-Sheng Wang at fswang302@163.com. Additional information Who can access the data: researchers whose proposed use of the data has been approved Types of analysis: Such requests are at the Academic Committee's discretion and dependent on the nature of the request, the merit of the research proposed, availability of the data and the intended use of the data. Mechanisms of data availability: After approval from the Academic Committee, this trial data can be shared with qualifying researchers who submit a proposal with a valuable research question. A contract should be signed. Any additional restrictions: NA.